Trends in the myocardial infarction market

Growth in incidences of cardiovascular diseases as well as hypertension, diabetes, and obesity. However, stringent regulatory policies by governing bodies coupled with the high cost of clinical trials impede.
The advancements in technology and the increase in acceptance of newer treatment technologies creating lucrative opportunities.
Government agencies and private insurers in developed nations are providing full-time coverage for cardiovascular imaging and acute care and drug therapies such as MI therapeutics to improve the cardiovascular health of the population.
The expected approval of stem cell therapies for MI, which are under the development phase, will have a positive impact on the adoption of myocardial infarction therapeutics. MI causes irreversible damage to the cardiac tissue. However, these myocardial tissues possess regenerative properties.
Expected technological breakthroughs will generate abundant opportunities for detecting targeted blockages, monitoring cellular response and for determining genetic predisposition, which might alternatively drive the growth of the myocardial infarction treatment.
According to the American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death.
Rise in the geriatric population base and growing cases of heart ailments are the main factor behind the dominance of North America myocardial infarction treatment.

Some of the trending players in Myocardial Infarction Market

Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies, Inc., and Pfizer Inc.